<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811287</url>
  </required_header>
  <id_info>
    <org_study_id>59044</org_study_id>
    <nct_id>NCT04811287</nct_id>
  </id_info>
  <brief_title>PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome</brief_title>
  <official_title>Utilizing Platelet-Rich Plasma as an Adjuvant to Carpal Tunnel Release for Severe Carpal Tunnel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Fredericson, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Factor Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the potential benefit of adjuvant platelet-rich plasma (PRP) with carpal&#xD;
      tunnel release (CTR) for patients with severe carpal tunnel syndrome (CTS). CTR is a rather&#xD;
      common procedure performed and seems to be quite effective for those with moderate CTS, but a&#xD;
      number of patients with severe CTS do not have quite the same response post-CTR. The&#xD;
      investigators will recruit patients who fall into the severe CTS category and compare CTR&#xD;
      with and without adjuvant PRP to see if PRP can improve outcomes of this common surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study team recruits patients with severe CTS who meet inclusion and exclusion criteria&#xD;
           in an outpatient hand surgery clinic. Patients will be consented by the research team if&#xD;
           the patient agrees to participate in the research study.&#xD;
&#xD;
        2. This will be a single blinded study, and participants will have an equal chance to be&#xD;
           placed in either group. Participants will be randomized using permuted block&#xD;
           randomization predetermined by our dedicated orthopedic biostatistician into two study&#xD;
           groups: those that undergo CTR with adjuvant intra-operative PRP and those that undergo&#xD;
           CTR without adjuvant PRP. All participants will have a pre-operative&#xD;
           electromyography/nerve conduction study (EMG/NCS).&#xD;
&#xD;
        3. Primary outcome measures (BCTQ and grip strength), and secondary outcome measures&#xD;
           (PROMIS; 2 point discrimination - thumb, index finger and middle finger; key pinch; 3&#xD;
           finger pinch; and EMG/NCS results) will be collected and stored in REDCap at initial&#xD;
           visit. BCTQ and PROMIS will actually be available online for patient to complete at the&#xD;
           patient's convenience.&#xD;
&#xD;
        4. Patients will undergo CTR with or without adjuvant PRP (based on assigned study group).&#xD;
           Patients will not know which group the subject is in (single blinded).&#xD;
&#xD;
        5. BCTQ and PROMIS will be collected online at 3 months, 6 months, and 12 months&#xD;
           post-operatively. EMG/NCS will only be performed preoperatively and at 12 months&#xD;
           post-operatively in the Sports Medicine clinic. At these visits, the investigators will&#xD;
           also collect data on 2 point discrimination, grip strength, key pinch, and 3 finger&#xD;
           pinch.&#xD;
&#xD;
        6. The investigators will store data in REDCap.&#xD;
&#xD;
        7. Data will be analyzed with the assistance of our biostatistician, and results will be&#xD;
           written up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized using permuted block randomization predetermined by our dedicated orthopedic biostatistician into two study groups: those that undergo CTR with adjuvant intra-operative PRP and those that undergo CTR without adjuvant PRP.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>See Model Description above.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Boston Carpal Tunnel Questionnaire</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Patient-reported questionnaire that examines symptom severity and overall functional status of patients with carpal tunnel syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boston Carpal Tunnel Questionnaire</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Patient-reported questionnaire that examines symptom severity and overall functional status of patients with carpal tunnel syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boston Carpal Tunnel Questionnaire</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Patient-reported questionnaire that examines symptom severity and overall functional status of patients with carpal tunnel syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Boston Carpal Tunnel Questionnaire</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Patient-reported questionnaire that examines symptom severity and overall functional status of patients with carpal tunnel syndrome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Measured with a dynamometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Measured with a dynamometer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Computer adaptive test developed to improve precision and reduce question burden for upper extremity conditions such as carpal tunnel syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>3 months post-op</time_frame>
    <description>Computer adaptive test developed to improve precision and reduce question burden for upper extremity conditions such as carpal tunnel syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>6 months post-op</time_frame>
    <description>Computer adaptive test developed to improve precision and reduce question burden for upper extremity conditions such as carpal tunnel syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System (PROMIS)</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Computer adaptive test developed to improve precision and reduce question burden for upper extremity conditions such as carpal tunnel syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Point Discrimination at Thumb</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Minimal distance that the patient feels 2 separate points of touch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Point Discrimination at Thumb</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Minimal distance that the patient feels 2 separate points of touch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Point Discrimination at Index Finger</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Minimal distance that the patient still feels 2 separate points of touch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Point Discrimination at Index Finger</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Minimal distance that the patient still feels 2 separate points of touch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Point Discrimination at Middle Finger</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Minimal distance that the patient still feels 2 separate points of touch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Point Discrimination at Middle Finger</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Minimal distance that the patient still feels 2 separate points of touch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Pinch</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Measured with a pinch meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key Pinch</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Measured with a pinch meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Finger Pinch</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>Measured with a pinch meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 Finger Pinch</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Measured with a pinch meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Motor Latency</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Motor Latency</measure>
    <time_frame>12 months post-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Motor Amplitude</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Motor Amplitude</measure>
    <time_frame>12 months post-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Sensory Latency</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Sensory Latency</measure>
    <time_frame>12 months post-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Sensory Amplitude</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Sensory Amplitude</measure>
    <time_frame>12 months post-op</time_frame>
    <description>From EMG/NCS data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMG of Abductor Pollicis Brevis</measure>
    <time_frame>up to 1 month pre-op</time_frame>
    <description>From EMG/NCS data - looking at spontaneous activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EMG of Abductor Pollicis Brevis</measure>
    <time_frame>12 months post-op</time_frame>
    <description>From EMG/NCS data - looking at spontaneous activity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <condition>PRP</condition>
  <arm_group>
    <arm_group_label>CTR with PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carpal tunnel release with adjuvant platelet-rich plasma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTR without PRP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Carpal tunnel release without adjuvant platelet-rich plasma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carpal Tunnel Release with Platelet-Rich Plasma</intervention_name>
    <description>CTR is performed with adjuvant PRP placed intra-operatively.</description>
    <arm_group_label>CTR with PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Carpal Tunnel Release without Platelet-Rich Plasma</intervention_name>
    <description>CTR is performed without adjuvant PRP placed intra-operatively.</description>
    <arm_group_label>CTR without PRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult age 18 years and up.&#xD;
&#xD;
          2. Diagnosed with severe CTS based on EMG/NCS, meaning those with evidence of axonal loss&#xD;
             (absent or low amplitude median sensory nerve action potential and/or absent or low&#xD;
             amplitude median motor nerve action potential and/or evidence of abnormal spontaneous&#xD;
             activity, reduced recruitment, or motor unit action potential changes on needle EMG of&#xD;
             median innervated muscles).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Younger than age 18 years (minor status).&#xD;
&#xD;
          2. Diagnosed with concomitant peripheral neuropathy.&#xD;
&#xD;
          3. Previous CTR on the affected side.&#xD;
&#xD;
          4. Have contraindications to PRP (platelet dysfunction syndrome, critical&#xD;
             thrombocytopenia, hemodynamic instability, septicemia, local infection at site of&#xD;
             procedure, consistent use of NSAIDs within 48 hours of procedure, steroid injection at&#xD;
             treatment site within 1 month, systemic use of steroids within 2 weeks, tobacco use,&#xD;
             recent fever or illness, or cancer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Donald Kasitinon, MD</last_name>
    <phone>469-371-7124</phone>
    <email>donald.kasitinon@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Kuwabara, MD</last_name>
    <email>amk1@stanford.edu</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Trull-Ahuir C, Sala D, Chismol-Abad J, Vila-Caballer M, Lis√≥n JF. Efficacy of platelet-rich plasma as an adjuvant to surgical carpal ligament release: a prospective, randomized controlled clinical trial. Sci Rep. 2020 Feb 7;10(1):2085. doi: 10.1038/s41598-020-59113-0.</citation>
    <PMID>32034241</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Michael Fredericson, MD</investigator_full_name>
    <investigator_title>Professor of Orthopaedic Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

